109 filings
8-K
SIOX
Sio Gene Therapies Inc.
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
8-K
SIOX
Sio Gene Therapies Inc.
15 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
SIOX
Sio Gene Therapies Inc.
14 Feb 23
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
7:01am
8-K
SIOX
Sio Gene Therapies Inc.
14 Dec 22
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
4:04pm
8-K
SIOX
Sio Gene Therapies Inc.
10 Nov 22
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
7:03am
8-K
famzn2o
14 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:08pm
8-K
1ax j1u9r1ibn
11 Aug 22
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
7:05am
8-K
gty1vr
14 Jun 22
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
7:01am
8-K
3toj7nj 7duoo
27 Apr 22
Sio Gene Therapies Provides Corporate Update
4:35pm
8-K
bk7th41e
18 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:21pm
8-K
6r1 i7ufi5
11 Feb 22
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
7:02am
8-K
iiwt 1e5gy0tgsar6upr
9 Feb 22
Regulation FD Disclosure
7:00am
8-K/A
4ge4r tu6mxq
31 Jan 22
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
0ig a8i9e8dfel6
31 Jan 22
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
4:08pm
8-K
gm3ofme8 vxes7a7ulck
25 Jan 22
Departure of Directors or Certain Officers
4:50pm
8-K
hrry31ab7l8lt7ed2
12 Nov 21
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
7:02am
8-K
po9meq
12 Nov 21
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy Program for Parkinson's Disease
12:00am
8-K
fwr 7gebo6okgef
1 Nov 21
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
7:00am
8-K
iwtprjt
21 Oct 21
Departure of Directors or Certain Officers
5:02pm
8-K
n8i9r 9cft9dwmwue9l
21 Oct 21
Regulation FD Disclosure
6:02am